These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33991513)

  • 1. Enfortumab vedotin for cisplatin-ineligible urothelial cancer.
    Pignot G
    Lancet Oncol; 2021 Jun; 22(6):748-749. PubMed ID: 33991513
    [No Abstract]   [Full Text] [Related]  

  • 2. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
    Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
    Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.
    Wu S; Adamson AS
    Dermatol Online J; 2019 Feb; 25(2):. PubMed ID: 30865407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
    Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
    Moussa M; Papatsoris A; Abou Chakra M; Dellis A
    Drug Des Devel Ther; 2021; 15():453-462. PubMed ID: 33603337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
    Molina GE; Schwartz B; Srinivas S; Shah S; Zaba LC
    Eur Urol; 2023 Apr; 83(4):377-378. PubMed ID: 36623949
    [No Abstract]   [Full Text] [Related]  

  • 9. Updates in the management and future landscape of urothelial carcinoma.
    Hanna KS; Campbell M; Kolling A; Husak A; Sturm S; Bello D; Blake K
    J Oncol Pharm Pract; 2021 Mar; 27(2):435-444. PubMed ID: 33143526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Bedke J; Maas M
    Eur Urol; 2021 Aug; 80(2):257-258. PubMed ID: 33895011
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A distinctive bullous skin reaction associated with enfortumab vedotin-ejfv treatment for metastatic urothelial cancer: A case report.
    Krause T; Bonnekoh H; Dilling A; Nast A; Metz M
    J Dtsch Dermatol Ges; 2021 Dec; 19(12):1781-1783. PubMed ID: 34786831
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
    Hirotsu KE; Rana J; Wang JY; Raghavan SS; Rieger KE; Srinivas S; Fan AC; Kwong BY; Novoa RA; Zaba LC
    J Am Acad Dermatol; 2021 Dec; 85(6):1610-1611. PubMed ID: 33301805
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis.
    Wang L; Shi G; Zhao G; He W; Cen Z; Xu F
    Anticancer Drugs; 2023 Apr; 34(4):473-478. PubMed ID: 36730481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
    Balar AV; Galsky MD; Rosenberg JE; Powles T; Petrylak DP; Bellmunt J; Loriot Y; Necchi A; Hoffman-Censits J; Perez-Gracia JL; Dawson NA; van der Heijden MS; Dreicer R; Srinivas S; Retz MM; Joseph RW; Drakaki A; Vaishampayan UN; Sridhar SS; Quinn DI; Durán I; Shaffer DR; Eigl BJ; Grivas PD; Yu EY; Li S; Kadel EE; Boyd Z; Bourgon R; Hegde PS; Mariathasan S; Thåström A; Abidoye OO; Fine GD; Bajorin DF;
    Lancet; 2017 Jan; 389(10064):67-76. PubMed ID: 27939400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
    Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
    Einstein DJ; Sonpavde G
    Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis.
    Parikh RB; Feld EK; Galsky MD; Adamson BJ; Cohen AB; Baxi SS; Boursi SB; Christodouleas JP; Vaughn DJ; Meropol NJ; Mamtani R
    Future Oncol; 2020 Jan; 16(2):4341-4345. PubMed ID: 31840537
    [No Abstract]   [Full Text] [Related]  

  • 19. Enfortumab Vedotin Checks Urothelial Cancer.
    Cancer Discov; 2019 Oct; 9(10):OF1. PubMed ID: 31519705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.